Emerging innovations in nanomedicine for cancer immunotherapy

被引:0
|
作者
Shah, Jaimin R. [1 ,2 ,3 ]
Kapoor, Devesh U. [4 ]
Prajapati, Bhupendra G. [1 ,5 ,6 ]
机构
[1] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92037 USA
[2] Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA
[3] Univ Calif San Diego, Program Mat Sci & Engn, La Jolla, CA 92093 USA
[4] Dr Dayaram Patel Pharm Coll, Bardoli 394601, Gujarat, India
[5] Ganpat Univ, Shree SK Patel Coll Pharmaceut Educ & Res, Kherva 384012, Gujarat, India
[6] Silpakorn Univ, Fac Pharm, Nakhon Pathom 73000, Nakhon Pathom P, Thailand
关键词
Nanomedicine; Tumor microenvironment; Immunotherapy; Gene therapy; Tumor specific antigen; PEGYLATED LIPOSOMAL DOXORUBICIN; TUMOR MICROENVIRONMENT; DENDRITIC CELLS; SOLID TUMORS; PHASE-I; NANOPARTICLES; CHALLENGES; DELIVERY; SIRNA; OPPORTUNITIES;
D O I
10.1016/j.jddst.2024.106584
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Cancer is characterized by a highly intricate pathophysiology and stands as a chief cause of mortality and illness globally. Traditional treatments for cancer such as chemotherapy, targeted & radiation therapy, and immunotherapy. Despite their widespread use, these therapies have significant limitations. They often suffer from a lack of selectivity, resulting in non-targeted cytotoxic effects that harm healthy tissues. Moreover, these treatments frequently encounter challenges such as inadequate drug delivery to sites of tumor and the development of multidrug resistance, which collectively diminish their overall effectiveness and potency in combating cancer. Nanoparticles (NPs) are increasingly employed as a nanomedicine platform in cancer immunotherapy, thanks to their exceptional physicochemical characteristics, such as size, shape, and surface attributes. This manuscript explores the challenges posed by the tumor microenvironment (TME) in cancer treatment and presents innovative strategies utilizing nanomaterials-based formulations. The resistance of the TME, particularly its physical and immunosuppressive barriers, impedes the efficacy of conventional therapies. We discuss the pharmacodynamics and pharmacokinetics of nanomaterials within the TME, highlighting their role in modifying cancerimmunity phenotypes. The regulation of the TME is critical, with a focus on modulating tumor blood vessels and extravascular components to enhance therapeutic outcomes. Additionally, the manuscript delves into the potential of nanomaterials-based immunotherapy, which can trigger the tumor-specific antigens release, facilitate their presentation, and prime T cells for effective anti-tumor responses. The integration of nanomaterialsbased delivery systems in combination immunotherapy is also explored, showcasing the synergy between nanomedicine and other therapeutic modalities, such as chemotherapy and gene therapy. This comprehensive review underscores the promise of nanomaterials in redefining cancer treatment by overcoming TME-associated resistance and improving immunotherapeutic efficacy.
引用
收藏
页数:14
相关论文
共 50 条
  • [41] Combining nanomedicine and immune checkpoint therapy for cancer immunotherapy
    Boone, Christine E.
    Wang, Lu
    Gautam, Aayushma
    Newton, Isabel G.
    Steinmetz, Nicole F.
    WILEY INTERDISCIPLINARY REVIEWS-NANOMEDICINE AND NANOBIOTECHNOLOGY, 2022, 14 (01)
  • [42] Sono/Photodynamic Nanomedicine-Elicited Cancer Immunotherapy
    Li, Yuce
    Xie, Jun
    Um, Wooram
    You, Dong Gil
    Kwon, Seunglee
    Zhang, Lianbin
    Zhu, Jintao
    Park, Jae Hyung
    ADVANCED FUNCTIONAL MATERIALS, 2021, 31 (12)
  • [43] Emerging Adjuvants for Cancer Immunotherapy
    Hu, Hong-Guo
    Li, Yan-Mei
    FRONTIERS IN CHEMISTRY, 2020, 8
  • [44] Emerging Trends in Immunotherapy for Cancer
    Mishra, Alok K.
    Ali, Amjad
    Dutta, Shubham
    Banday, Shahid
    Malonia, Sunil K.
    DISEASES, 2022, 10 (03)
  • [45] Emerging targets in cancer immunotherapy
    Burugu, Samantha
    Dancsok, Amanda R.
    Nielsen, Torsten O.
    SEMINARS IN CANCER BIOLOGY, 2018, 52 : 39 - 52
  • [46] Emerging nanotechnologies for cancer immunotherapy
    Shukla, Sourabh
    Steinmetz, Nicole F.
    EXPERIMENTAL BIOLOGY AND MEDICINE, 2016, 241 (10) : 1116 - 1126
  • [47] Emerging Concepts in Cancer immunotherapy
    Schlom, Jeffrey
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2017, 74 : 41 - 41
  • [48] Supramolecular Assembled Programmable Nanomedicine As In Situ Cancer Vaccine for Cancer Immunotherapy
    Zhang, Yu
    Ma, Sheng
    Liu, Xinming
    Xu, Yudi
    Zhao, Jiayu
    Si, Xinghui
    Li, Hongxiang
    Huang, Zichao
    Wang, Zhenxin
    Tang, Zhaohui
    Song, Wantong
    Chen, Xuesi
    ADVANCED MATERIALS, 2021, 33 (07)
  • [49] Polymeric Nanoreactors as Emerging Nanoplatforms for Cancer Precise Nanomedicine
    Li, Xin
    Zhao, Xiaopeng
    Lv, Runkai
    Hao, Linhui
    Huo, Fengwei
    Yao, Xikuang
    MACROMOLECULAR BIOSCIENCE, 2021, 21 (06)
  • [50] Emerging cytokine delivery with nanomedicine for brain cancer treatment
    Sousa, Flavia
    EXPERT OPINION ON DRUG DELIVERY, 2024, 21 (04) : 513 - 516